KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Amustaline/glutathione pathogen-reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial.

Ian J Welsby, Michael E Sekela, Edward L Snyder, James D Gorham, John S McNeil, Kathy Liu, Stanley Bentow, Thomas Gniadek, Laurence Corash, Nina Mufti, Richard J Benjamin, ReCePI Study Group

Transfusion 66(1) 72-83

PMID41317318
PMCIDPMC12857873
DOI10.1111/trf.70009
发表日期2025-11-29
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图。
摘要

摘要

BACKGROUND: The ReCePI randomized, controlled trial compared amustaline/glutathione pathogen-reduced (PR) and conventional red blood cell (RBC) transfusions in cardiac surgery. STUDY DESIGN AND METHODS: We performed a post-hoc analysis of hemoglobin (Hb) utilization and safety outcomes. Hb content of study RBCs was measured at manufacture. Subject Hb levels, estimated blood loss and blood product use were recorded during and for 7 days post-surgery. Acute kidney injury (AKI) incidence was graded over 7 days, and adverse events were assessed for 28 days. RESULTS: PR-RBCs contained 5.2% less Hb (mean [SD] Test 58.1 [6.5] g; Control 61.5 [6.8] g Hb, p < .001) due to manufacturing volume losses. Four hundred fifty-six PR- and 524 conventional RBCs were transfused to 159 Test and 162 Control subjects, respectively. Mean subject baseline and post-surgery Hb levels, and blood loss were not different between groups. Test subjects tended to require fewer total RBCs (3.5 [2.7] Test vs. 4.0 [3.5] Control, p = .08) resulting in 17.6% significantly less mean total Hb transfused (Test 203.2 g; Control 246.8 g Hb, p = .01). The proportions of subjects transfused with, and the number of platelet and cryoprecipitate units transfused were not different. Test subjects received less plasma (2.3 [1.8] units Test vs. 3.5 [3.8] Control, p = .03). Overall incidence of adverse events and AKI were not clinically different. Imbalances in AKI severity (Grade III Test 15/159 [9.4%]; Control 7/162 [4.3%], p = .07) may suggest under-transfusion in the highest-risk Test subjects. DISCUSSION: Test patients required less transfused Hb than control subjects to maintain equivalent daily hemoglobin levels following similar blood loss.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Distribution of mean hemoglobin content of transfused study red blood cells.
非 KM Figure
FIGURE 2Correlation of mean baseline and day 2 post‐surgery hemoglobin levels by site (all transfused subjects—combined test and control data).
非 KM Figure
FIGURE 3Number of study (blue) and non‐study (red) RBC transfusions during the 7‐day acute transfusion period. Six of 48 (12.5%) Control and 11 of 32 (34.4%) Test subjects who received ≥5 total study and non‐study RBC units in the 7‐day transfusion period also experienced Stage III AKI.
非 KM Figure
FIGURE 4Impact of incremental non‐study RBCs on acute kidney injury (KDIGO) incidence at 7 days post‐surgery. mITT, modified intention‐to‐treat including all study and non‐study RBCs; SRO, study RBC only. The differences in the trends are not statistically significant ( p > .05).
非 KM Figure